URB602 is primarily used in research settings as a selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH). By inhibiting FAAH, URB602 increases levels of endogenous cannabinoids such as anandamide, which play roles in pain modulation, mood regulation, and inflammation control. This makes URB602 a valuable tool in studying the endocannabinoid system and its involvement in conditions like anxiety, depression, chronic pain, and neurodegenerative diseases. It has also been explored in preclinical models for its potential anti-inflammatory and neuroprotective effects, particularly in conditions such as multiple sclerosis and Parkinson’s disease. Due to its ability to modulate cannabinoid signaling without direct receptor activation, URB602 offers a targeted approach for investigating therapeutic strategies with potentially fewer side effects compared to direct cannabinoid agonists.